ArticleLife (Basel, Switzerland)2022
Fetal Membranes Contribute to Drug Transport across the Feto-Maternal Interface Utilizing the Breast Cancer Resistance Protein (BCRP).
Article in Life (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Advancements in extracellular vesicle research.Extracellular vesicle · 2026Article
- Adenosine triphosphate-binding cassette transporters: key players in maintaining fetal health during pregnancy.Frontiers in endocrinology · 2026Review
- A call to standardize the nomenclature of human fetal membrane at the feto-maternal interface.Placenta · 2025Review
- Exofection by exosomes: A transient functional cargo transfer.Extracellular vesicle · 2025Article
- Microfluidic device successfully replaces traditional models of pregnancy associated drug pharmacokinetic studies.Pregnancy (Hoboken, N.J.) · 2025Article
- Determining Sex-Specific Gene Expression Differences in Human Chorion Trophoblast Cells.International journal of molecular sciences · 2025Article
- Article
- Modeling reproductive and pregnancy-associated tissues using organ-on-chip platforms: challenges, limitations, and the high throughput data frontier.Frontiers in bioengineering and biotechnology · 2025Review
- PGRMC2 and HLA-G regulate immune homeostasis in a microphysiological model of human maternal-fetal membrane interface.Communications biology · 2024Article
- Endocrine-disrupting compounds and their impact on human placental function: evidence from placenta organ-on-chip studies.Lab on a chip · 2024Article
- Implications of BCRP modulation on PTZ-induced seizures in mice: Role of ko143 and metformin as adjuvants to lamotrigine.Naunyn-Schmiedeberg's archives of pharmacology · 2023Article
- Emerging Roles of Endocannabinoids as Key Lipid Mediators for a Successful Pregnancy.International journal of molecular sciences · 2023Review
- The Role of Fetal Membranes during Gestation, at Term, and Preterm Labor.Placenta and reproductive medicine · 2023Article
- Microfluidic technology and simulation models in studying pharmacokinetics during pregnancy.Frontiers in pharmacology · 2023Article
- Extracellular Vesicles-mediated recombinant IL-10 protects against ascending infection-associated preterm birth by reducing fetal inflammatory response.Frontiers in immunology · 2023Article
- Testing of drugs using human feto-maternal interface organ-on-chips provide insights into pharmacokinetics and efficacy.Lab on a chip · 2022Article
- Expression of CYP450 enzymes in human fetal membranes and its implications in xenobiotic metabolism during pregnancy.Life sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
During pregnancy, the placenta is established as a primary organ for drug transport at the maternal-fetal interface. The fetal membranes (FM) also form an interface with maternal tissues; however, their role in drug transport has not been previously investigated. Knowledge of drug transport across this feto-maternal interface along with the placenta can improve new drug development and testing for use during pregnancy. We also hypothesize that extracellular vesicles (exosomes 30-160 nm) released from the FM and placental cells may also contain drug transport proteins and might impact drug trafficking across the feto-maternal interfaces. The objectives were to (1) localize the breast cancer resistance protein (BCRP) in human FM; (2) determine the drug transport function of BCRP in chorion trophoblast cells (CTCs) of the FM; and (3) investigate the presence of BCRP in FM cell-derived exosomes, as a paracrine modifier of the tissue environment for transport functions. The gene and protein expressions of ABCG2/BCRP in FMs were determined by quantitative real-time PCR (qRT-PCR) and western blotting (WB) and were localized by immunohistochemistry (IHC). The surface expression of BCRP in FM cells was determined by flow cytometry. The functional role of BCRP was assessed by an EFFLUX dye multidrug resistance assay. The presence of BCRP in exosomes derived from CTCs and BeWo cells was examined using ExoView
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.